The neuroprotective effects of ketamine in post-cardiac arrest patients have garnered significant attention in recent years, particularly due to its potential to mitigate the neurological damage that often follows cardiac arrest. Ketamine, an NMDA receptor antagonist, has been shown to possess neuroprotective properties, which may be beneficial in the context of post-cardiac arrest syndrome characterized by hypoxic-ischemic brain injury (HIBI) (Ornowska et al., 2022; Katz et al., 2021).
Research indicates that the development of post-cardiac arrest brain injury (PCABI) is a critical determinant of mortality and neurological outcomes in patients who have experienced cardiac arrest. In fact, PCABI is responsible for approximately 68% of deaths in out-of-hospital cardiac arrest cases, underscoring the need for effective neuroprotective strategies (Ornowska et al., 2022). Ketamine's ability to enhance early survival rates in experimental models of cardiac arrest has been demonstrated, with studies showing that pretreatment with ketamine significantly increased survival rates in rat models (Kuklin et al., 2019). This suggests that ketamine may play a role in improving outcomes by reducing excitotoxicity and oxidative stress, both of which are pivotal in the pathophysiology of brain injury following cardiac arrest (Katz et al., 2021).
In addition to ketamine, other neuroprotective strategies such as targeted temperature management (TTM) have been established as effective interventions in post-cardiac arrest care. TTM has been shown to improve neurological recovery and reduce mortality rates in comatose patients after cardiac arrest (Sandroni et al., 2022). The combination of TTM with pharmacological agents like ketamine may provide a synergistic effect, enhancing neuroprotection and improving overall outcomes (Cotter, 2023). Furthermore, the management of hemodynamic variables, including maintaining normoxia and normocapnia, is crucial in optimizing cerebral perfusion and mitigating secondary brain injury (Cotter, 2023; Kovács & Zima, 2017).
The complexity of the neuroprotective mechanisms involved in post-cardiac arrest care necessitates a multifaceted approach. Ketamine's role as a neuroprotective agent is supported by its ability to inhibit calcium wave propagation and reduce neuronal excitotoxicity (Xu et al., 2017). Additionally, the use of adjunctive therapies, such as progesterone and other neurotrophic factors, has been explored, although their efficacy remains inconclusive (Qafiti et al., 2021; Wegrzyn et al., 2019). The integration of these various strategies, including ketamine administration, may ultimately enhance the neuroprotective landscape for patients recovering from cardiac arrest.
In conclusion, the neuroprotective effects of ketamine in post-cardiac arrest patients are supported by a growing body of evidence highlighting its potential to improve survival and neurological outcomes. The combination of ketamine with established neuroprotective strategies, such as TTM and careful hemodynamic management, presents a promising avenue for enhancing recovery in this vulnerable patient population.
References:
- Cotter, E. (2023). Post-cardiac arrest care in the intensive care unit. International Anesthesiology Clinics, 61(4), 71-78.
https://doi.org/10.1097/aia.0000000000000418
- Katz, A., Brosnahan, S., Papadopoulos, J., Parnia, S., & Lam, J. (2021). Pharmacologic neuroprotection in ischemic brain injury after cardiac arrest. Annals of the New York Academy of Sciences, 1507(1), 49-59.
https://doi.org/10.1111/nyas.14613
- Kovács, E. and Zima, E. (2017). Strategies of neuroprotection after successful resuscitation..
https://doi.org/10.5772/intechopen.70593
- Kuklin, V., Akhatov, N., Kondratiev, T., Konkayev, A., Baigenzhin, A., Konkayeva, M., … & Dahl, V. (2019). The influences of morphine or ketamine pre-treatment on hemodynamic, acid-base status, biochemical markers of brain damage and early survival in rats after asphyxial cardiac arrest..
https://doi.org/10.21203/rs.2.354/v2
- Ornowska, M., Wormsbecker, A., Andolfatto, G., Leung, T., Khan, I., & Medvedev, G. (2022). The use of ketamine as a neuroprotective agent following cardiac arrest: a scoping review of current literature. CNS Neuroscience & Therapeutics, 29(1), 104-110.
https://doi.org/10.1111/cns.13983
- Qafiti, F., Rubay, D., Shin, R., Lottenberg, L., & Borrego, R. (2021). Therapeutic hypothermia with progesterone improves neurologic outcomes in ventricular fibrillation cardiac arrest after electric shock. Cureus.
https://doi.org/10.7759/cureus.15749
- Sandroni, C., Natalini, D., & Nolan, J. (2022). Temperature control after cardiac arrest. Critical Care, 26(1).
https://doi.org/10.1186/s13054-022-04238-z
- Wegrzyn, D., Kutwin-Chojnacka, A., Bilski, J., Mroszczyk, K., & Węgrzyn, K. (2019). Neurotrophic factors in the treatment of acute brain hypoxia secondary to cardiac arrest: a case report. Journal of Medicine and Life, 12(3), 233-235.
https://doi.org/10.25122/jml-2019-1007
- Xu, D., Wang, B., Zhao, X., Zheng, Y., Du, J., & Wang, Y. (2017). General anesthetics protects against cardiac arrest-induced brain injury by inhibiting calcium wave propagation in zebrafish. Molecular Brain, 10(1).
https://doi.org/10.1186/s13041-017-0323-x